Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Breaking the jar: Why NeuroAI needs embodiment
Brain function is inexorably shaped by the body. Embracing this fact will benefit computational models of real brain function, as well as the design of artificial neural networks.
Breaking the jar: Why NeuroAI needs embodiment
Brain function is inexorably shaped by the body. Embracing this fact will benefit computational models of real brain function, as well as the design of artificial neural networks.
Quantifying funding sources across neuroscience labs
We want to hear from you about the sources of funding for your research.
Quantifying funding sources across neuroscience labs
We want to hear from you about the sources of funding for your research.
What kinds of support do early-career researchers need?
Help The Transmitter and Neuromatch bolster the next generation of neuroscientists.
What kinds of support do early-career researchers need?
Help The Transmitter and Neuromatch bolster the next generation of neuroscientists.